@Roonerspismed
Regarding the earlier nano chat - again, the blind faith placed in “scientists” astounds me
Lots remain unknown about the pharmokinetics of nanoparticles.
Interesting article in this year’s International Journal of Molecular Medicine summarising where we are. I’m amazed at the experimental use of it in billions of people.
It makes me very uncomfortable should there later be longer term neurological issues.
I profoundly hope I’m wrong, I spend far more time worrying about this than I ever did covid
Since you couldn't be arsed to provide a link, here it is:
Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)
It was published in May 2020, long before any of the vaccines entered clinical trials. Here's the conclusion, which contains exactly zero concerns about nanoparticles. Did you leave out the link, hoping no one would bother to look it up?
- Conclusion and future perspectives
Scientists began working on coronavirus vaccines during SARS and MERS outbreaks, but their efforts did not materialize because of a myriad of difficulties. Since this extremely severe current coronavirus pandemic, COVID-19, the spread of the outbreak appears much broader than was the case for SARS. There is also the possibility of the disease becoming endemic and seasonal in its appearance, according to some investigators. This explains why many research groups and companies are undertaking efforts to develop an effective vaccine against SARS-CoV-2 all over the world, also speeding up all the usual phases needed to develop and test a vaccine in the human.
An important feature in the landscape of vaccine research and development for SARS-COV-2 is represented by the varied range of evaluated technological platforms, including nucleic acids (DNA and RNA), virus-like particles, peptides, viral vector (replicative and non-replicative), recombinant proteins, live attenuated viruses and inactivated viruses. Many of these platforms are not currently the basis of vaccines already authorized, but experience in areas such as oncology encourages developers to exploit new opportunities for increased development and manufacturing speeds.
There is not an effective therapy for severe COVID-19, and social distancing is extremely 'costly' from a social and economic perspective. Therefore, the development of an effective vaccine, along with efforts to implement immune-enhancing strategic treatments and shorter-term efforts to identify tactical repurposed treatments, should be considered major public health priorities. We hope to get this key tool for disease prevention, and to do this quite soon.
It is unknown whether there ever will be a successful SARS-CoV-2 vaccine, but the efforts of the scientific community in attempting to develop such a vaccine is without precedent. Thus, COVID-19 vaccines are a never ending story.